Compare · CCEL vs PARK
CCEL vs PARK
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Park Dental Partners Inc. (PARK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and PARK operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PARK is the larger of the two at $84.7M, about the same size as CCEL ($83.3M).
- Over the past year, CCEL is down 30.4% and PARK is up 84.6% - PARK leads by 115.0 points.
- CCEL has been more active in the news (2 items in the past 4 weeks vs 1 for PARK).
- PARK has more recent analyst coverage (2 ratings vs 0 for CCEL).
- Company
- Cryo-Cell International Inc.
- Park Dental Partners Inc.
- Price
- $3.41-3.94%
- $19.38-1.72%
- Market cap
- $83.3M
- $84.7M
- 1M return
- -7.21%
- +8.75%
- 1Y return
- -30.41%
- +84.57%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2025
- News (4w)
- 2
- 1
- Recent ratings
- 0
- 2
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest CCEL
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
Latest PARK
- Park Dental Partners Announces Dates for Second Quarter 2026 Earnings Release and Conference Call
- SEC Form 4 filed by Director Smith Philip Irving
- SEC Form 4 filed by CEO and Chairman Swenson Peter G
- SEC Form 4 filed by Officer Steele Christopher Eugene
- SEC Form 4 filed by Director Smith Christopher Charles
- SEC Form 4 filed by Chief Financial Officer Bernander Christopher James
- SEC Form 4 filed by Director Schaefer Anna Marie
- SEC Form 4 filed by Officer Law Alan Siems
- Amendment: SEC Form SCHEDULE 13G/A filed by Park Dental Partners Inc.
- Park Dental Partners Expands Presence in Rochester, Minn., with Addition of Zumbro View Dental